Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma

BACKGROUND: The potential therapeutic efficacy of daratumumab in natural killer T-cell lymphoma (NKTL) was highlighted when its off-label usage produced sustained remission in a patient with highly refractory disease. This is corroborated recently by a phase II clinical trial which established that...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Immunother Cancer
Κύριοι συγγραφείς: Mustafa, Nurulhuda, Nee, Adina Huey Fang, Chooi, Jing Yuan, Toh, Sabrina Hui Min, Chung, Tae-Hoon, Selvarajan, Viknesvaran, Fan, Shuangyi, Ng, Siok Bian, Poon, Michelle, Chan, Esther, Lee, Joanne, Chee, Yen Lin, Jeyasekharan, Anand D, Zhou, Longen, Yang, Jennifer, Chng, Wee Joo
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: BMJ Publishing Group 2021
Θέματα:
Basic Tumor Immunology
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8256838/
https://ncbi.nlm.nih.gov/pubmed/34215687
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-002123
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια